Research programme: cancer immunotherapeutics - Affibody/ Lokon Pharma
Latest Information Update: 25 Jan 2022
At a glance
- Originator Affibody; Lokon Pharma
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses; Proteins
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer